Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 9/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20733208 | 0.81 | GSK3B (0.35) | RPS6KA3JAK2AXLGSK3BDYRK1A | |
| SCHEMBL20733150 | 0.78 | PTGER4 (0.39) | RPS6KA3 | |
| SCHEMBL19736443 | 0.78 | GSK3B (0.39) | RPS6KA3CNR2CNR1GSK3BDYRK1A | |
| SCHEMBL20733244 | 0.71 | FGFR4 (0.37) | RPS6KA3 | |
| SCHEMBL20733310 | 0.71 | ALDH1A1 (0.35) | — | |
| SCHEMBL17769426 | 0.71 | CNR2 (0.40) | CNR2JAK2AXLCNR1 | |
| SCHEMBL17769423 | 0.71 | CNR2 (0.40) | CNR2JAK2AXLCNR1 | |
| SCHEMBL17776462 | 0.70 | CNR2 (0.37) | CNR2AXLCNR1 | |
| SCHEMBL17770047 | 0.70 | CNR2 (0.37) | CNR2AXLCNR1 | |
| SCHEMBL17770046 | 0.70 | CNR2 (0.37) | CNR2AXLCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RPS6KA3 1949/4885CNR2 3062/4885JAK2 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.